Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GW signs Otsuka as cannabis drug partner
The deal will see UK-based GW receive milestone payments of up to $273 million, including a signature fee of $18 million from Otsuka. In addition, Otsuka will bear
The deal will see UK-based GW receive milestone payments of up to $273 million, including a signature fee of $18 million from Otsuka. In addition, Otsuka will bear
Sales increased 11.6% to GBP1.5 billion, driven by the expansion of healthcare services and an increased demand for medical electrical products. Lloydspharmacy increased its services for Primary Care
The launch of the erythropoiesis-stimulating agent, which increases the production of red blood cells, coincides with an FDA warning on the drug class. The US drug regulator recently
SCOLR Pharma said it planned to continue the development of a 12-hour extended release ibuprofen product and would either seek to work with another large pharmaceutical company or
The phase III TeloVac trial has been designed by the Pancreatic Cancer Clinical Sub-Group of the UK National Cancer Research Institute and will be run by Cancer Research
The decision was based on five, company-sponsored pediatric studies conducted at the request of the FDA, according to J&J. The extension gives the company marketing exclusivity on Levaquin
Medicare announced a national coverage analysis on the use of erythropoiesis stimulating agents (ESAs) for the conditions other than end-stage renal disease, the first step toward issuing a
The company, which specializes in the prevention and treatment of infectious diseases, has filed a notice of appeal at the Civilian Board of Contract Appeals regarding the contract
In the first stage of the trial, a group of 13 patients with relapsing CBCL will be enrolled at centers in the US, France and Switzerland. If the
Orphan drug status is given by the US regulators to compounds that can treat rare diseases, defined as those affecting fewer than 200,000 Americans. The designation gives the